Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate vs sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia
2006-004959-38Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2007
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lanthanum carbonate and sevelamer carbonate in hyperphosphatemia and end-stage kidney disease (ESKD) (2 arms), sponsored by Takeda. Primary endpoint: Change from baseline in serum phosphorus levels. Started Jan 2007; status: completed.
02
Drugs
lanthanum carbonatesevelamer carbonate
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2006-004959-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004959-38.